Janssen/Legend’s Cilta-Cel Responses Could Make Up For Second-To-Market Position

Mitigation Strategy Lessens Neurotoxicity Of CAR-T In Myeloma

Cilta-cel likely will be the second BCMA-targeting CAR-T therapy approved in the US for multiple myeloma, but appears to have an efficacy advantage over BMS/bluebird’s first-to-market Abecma.

Red number two inside a white circle and an arrow painted on concrete
The US FDA will decide whether to approve cilta-cel by 29 November • Source: Alamy

Already approved BCMA-targeting chimeric antigen receptor T-cell therapeutic Abecma (idecabtagene vicleucel) from Bristol Myers Squibb Company and bluebird bio has an eight-month head start over Janssen Pharmaceutical Cos. and Legend Biotech Corp.’s pending ciltacabtagene autoleucel (cilta-cel), but updated pivotal trial data for cilta-cel show response rates that could give the runner-up an advantage in the multiple myeloma market.

Janssen and Legend’s B-cell maturation antigen (BCMA)-targeting CAR-T therapy cilta-cel is under priority review at the US Food and Drug...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D